A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401

Trial Profile

A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Nov 2015

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Pseudomonal infections; Respiratory tract infections
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 05 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
    • 05 Sep 2014 Status changed from recruiting to active, no longer recruiting.
    • 24 Jan 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01775137).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top